-Reuters Citing China State Media
Piper Sandler Maintains Neutral on Zynex, Raises Price Target to $10
Piper Sandler analyst Adam Maeder maintains Zynex (NASDAQ:ZYXI) with a Neutral and raises the price target from $7 to $10.
Related Posts
Allergan To End Around 3,000 Opioid Lawsuits With Over $2B In Settlement: Report
AbbVie Inc’s (NYSE:ABBV) Allergan unit has agreed to pay more than $2 billion to resolve over 3,000 lawsuits filed…
CorMedix Inc. Announces Notice Of Allowance For U.S. Patent Application Covering Lead Product DefenCath
CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced that
Inseego Voluntarily Pays-Off And Terminates Asset-Backed Loan Facility To Improve Capital Structure Flexibility And Meaningfully Reduce Financing Costs
Elimination of restrictive borrowing facility provides for more efficient debt capacity and cash managementInseego Corp. (NASDAQ:INSG) (the "Company"), a technology leader in 5G mobile and fixed wireless solutions for